Results in Figure S54 revealed that either IFNγ or Zole (dispersed in gel, respectively) could mildly restrain CT26 tumor growth after iRFA, and their combination (IFNγ and Zole dispersed in gel simultaneously) showed better anti-tumor effect. The gene discussed is IFNG; the disease is neoplasm.